High Potency APIs /HPAPI Market

Executive Summary

High Potency APIs /HPAPI Market was valued at US $24.55 billion in 2021 and is projected to grow at 8.56% CAGR over the forecast period to reach US $40.17 billion by 2027. High Potency APIs /HPAPI Market represented US $3.72 billion opportunity over 2019-2021 and estimated to create US $15.63 billion opportunity in 2027 over 2021.

High Potency APIs /HPAPI from Consainsights analyses the High Potency APIs /HPAPI Market in the Life Sciences industry over the forecast period to 2027.

High Potency APIs /HPAPI research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

High Potency APIs /HPAPI segmentation includes Type, Type of Synthesis, Type of Manufacturer, Therapeutic Application, Region and Geography.

Based on the Type, the High Potency APIs /HPAPI analysis covers Innovative High-Potency Active Pharmaceutical Ingredients, Generic High-Potency Active Pharmaceutical Ingredients.

In Type segment, Innovative High-Potency Active Pharmaceutical Ingredients segment has highest cagr growth of 7.57%.

Based on the Type of Synthesis, the High Potency APIs /HPAPI analysis covers Synthetic High-Potency Active Pharmaceutical Ingredients, Biotech High-Potency Active Pharmaceutical Ingredients.

In Type of Synthesis segment, Synthetic High-Potency Active Pharmaceutical Ingredients segment has highest cagr growth of 7.57%.

Based on the Type of Manufacturer, the High Potency APIs /HPAPI analysis covers Captive HPAPI Manufacturers, Merchant HPAPI Manufacturers.

In Type of Manufacturer segment, Captive HPAPI Manufacturers segment has highest cagr growth of 7.57%.

Based on the Therapeutic Application, the High Potency APIs /HPAPI analysis covers Oncology, Hormonal Imbalance, Glaucoma, Other Therapeutic Applications.

In Therapeutic Application segment, Oncology segment has highest cagr growth of 7.57%.

Based on the Region, the High Potency APIs /HPAPI analysis covers North America, Europe, Asia, Rest of the World (RoW).

In Region segment, North America segment has highest cagr growth of 7.57%.

Based on the region, the High Potency APIs /HPAPI analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Pfizer, Novartis International AG, Sanofi, F. Hoffmann-La Roche, Bristol-Myers Squibb, Boehringer Ingelheim, Teva Pharmaceutical Industries, ELI Lilly and Company, Merck, Abbvie, Mylan, Bayer and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, Innovative High-Potency Active Pharmaceutical Ingredients segment has the highest revenue of US $17.95 billion and is expected to grow at CAGR of 7.57% by 2027 Innovative High-Potency Active Pharmaceutical Ingredients segment has highest cagr growth of 7.57%.

Innovative High-Potency Active Pharmaceutical Ingredients

Innovative High-Potency Active Pharmaceutical Ingredients segment was valued at US $15.23 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $29.39 billion by 2027. Innovative High-Potency Active Pharmaceutical Ingredients segment represented US $2.72 billion opportunity over 2019-2021 and estimated to create US $11.43 billion opportunity in 2027 over 2021.

Generic High-Potency Active Pharmaceutical Ingredients

Generic High-Potency Active Pharmaceutical Ingredients segment was valued at US $5.59 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $10.79 billion by 2027. Generic High-Potency Active Pharmaceutical Ingredients segment represented US $1.00 billion opportunity over 2019-2021 and estimated to create US $4.20 billion opportunity in 2027 over 2021.

Type of Synthesis

Introduction

In 2021, Synthetic High-Potency Active Pharmaceutical Ingredients segment has the highest revenue of US $21.16 billion and is expected to grow at CAGR of 7.57% by 2027 Synthetic High-Potency Active Pharmaceutical Ingredients segment has highest cagr growth of 7.57%.

Synthetic High-Potency Active Pharmaceutical Ingredients

Synthetic High-Potency Active Pharmaceutical Ingredients segment was valued at US $17.96 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $34.63 billion by 2027. Synthetic High-Potency Active Pharmaceutical Ingredients segment represented US $3.20 billion opportunity over 2019-2021 and estimated to create US $13.47 billion opportunity in 2027 over 2021.

Biotech High-Potency Active Pharmaceutical Ingredients

Biotech High-Potency Active Pharmaceutical Ingredients segment was valued at US $2.87 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.54 billion by 2027. Biotech High-Potency Active Pharmaceutical Ingredients segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $2.16 billion opportunity in 2027 over 2021.

Type of Manufacturer

Introduction

In 2021, Captive HPAPI Manufacturers segment has the highest revenue of US $13.54 billion and is expected to grow at CAGR of 7.57% by 2027 Captive HPAPI Manufacturers segment has highest cagr growth of 7.57%.

Captive HPAPI Manufacturers

Captive HPAPI Manufacturers segment was valued at US $11.49 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $22.17 billion by 2027. Captive HPAPI Manufacturers segment represented US $2.05 billion opportunity over 2019-2021 and estimated to create US $8.62 billion opportunity in 2027 over 2021.

Merchant HPAPI Manufacturers

Merchant HPAPI Manufacturers segment was valued at US $9.33 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $18.01 billion by 2027. Merchant HPAPI Manufacturers segment represented US $1.67 billion opportunity over 2019-2021 and estimated to create US $7.00 billion opportunity in 2027 over 2021.

Therapeutic Application

Introduction

In 2021, Oncology segment has the highest revenue of US $10.54 billion and is expected to grow at CAGR of 7.57% by 2027 Oncology segment has highest cagr growth of 7.57%.

Oncology

Oncology segment was valued at US $8.95 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $17.26 billion by 2027. Oncology segment represented US $1.60 billion opportunity over 2019-2021 and estimated to create US $6.71 billion opportunity in 2027 over 2021.

Hormonal Imbalance

Hormonal Imbalance segment was valued at US $4.39 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $8.46 billion by 2027. Hormonal Imbalance segment represented US $0.78 billion opportunity over 2019-2021 and estimated to create US $3.29 billion opportunity in 2027 over 2021.

Glaucoma

Glaucoma segment was valued at US $4.47 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $8.62 billion by 2027. Glaucoma segment represented US $0.80 billion opportunity over 2019-2021 and estimated to create US $3.35 billion opportunity in 2027 over 2021.

Other Therapeutic Applications

Other Therapeutic Applications segment was valued at US $3.02 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.83 billion by 2027. Other Therapeutic Applications segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.27 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $10.90 billion and is expected to grow at CAGR of 7.57% by 2027 North America segment has highest cagr growth of 7.57%.

North America

North America segment was valued at US $9.25 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $17.85 billion by 2027. North America segment represented US $1.65 billion opportunity over 2019-2021 and estimated to create US $6.94 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $5.60 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $10.80 billion by 2027. Europe segment represented US $1.00 billion opportunity over 2019-2021 and estimated to create US $4.20 billion opportunity in 2027 over 2021.

Asia

Asia segment was valued at US $2.88 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.56 billion by 2027. Asia segment represented US $0.51 billion opportunity over 2019-2021 and estimated to create US $2.16 billion opportunity in 2027 over 2021.

Rest of the World (RoW)

Rest of the World (RoW) segment was valued at US $3.09 billion in 2019 and is projected to grow at 7.57% CAGR over the forecast period to reach US $5.96 billion by 2027. Rest of the World (RoW) segment represented US $0.55 billion opportunity over 2019-2021 and estimated to create US $2.32 billion opportunity in 2027 over 2021.